BR112019018447A2 - formas sólidas e composições de combinação compreendendo um inibidor da beta-lactamase e usos das mesmas - Google Patents
formas sólidas e composições de combinação compreendendo um inibidor da beta-lactamase e usos das mesmas Download PDFInfo
- Publication number
- BR112019018447A2 BR112019018447A2 BR112019018447-3A BR112019018447A BR112019018447A2 BR 112019018447 A2 BR112019018447 A2 BR 112019018447A2 BR 112019018447 A BR112019018447 A BR 112019018447A BR 112019018447 A2 BR112019018447 A2 BR 112019018447A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- injection
- composition according
- solvate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762467750P | 2017-03-06 | 2017-03-06 | |
| US201762467752P | 2017-03-06 | 2017-03-06 | |
| US62/467,752 | 2017-03-06 | ||
| US62/467,750 | 2017-03-06 | ||
| US201762564989P | 2017-09-28 | 2017-09-28 | |
| US201762564990P | 2017-09-28 | 2017-09-28 | |
| US62/564,989 | 2017-09-28 | ||
| US62/564,990 | 2017-09-28 | ||
| PCT/US2018/020968 WO2018165048A1 (en) | 2017-03-06 | 2018-03-05 | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019018447A2 true BR112019018447A2 (pt) | 2020-04-14 |
Family
ID=63448038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019018447-3A BR112019018447A2 (pt) | 2017-03-06 | 2018-03-05 | formas sólidas e composições de combinação compreendendo um inibidor da beta-lactamase e usos das mesmas |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US11091505B2 (enExample) |
| EP (1) | EP3592362B1 (enExample) |
| JP (2) | JP7634934B2 (enExample) |
| KR (1) | KR102603489B1 (enExample) |
| CN (2) | CN117398398A (enExample) |
| AU (1) | AU2018230991B2 (enExample) |
| BR (1) | BR112019018447A2 (enExample) |
| CA (1) | CA3055253A1 (enExample) |
| ES (1) | ES3015371T3 (enExample) |
| HR (1) | HRP20250459T1 (enExample) |
| IL (2) | IL268981B2 (enExample) |
| MA (1) | MA47743A (enExample) |
| MY (1) | MY196966A (enExample) |
| PH (1) | PH12019502037B1 (enExample) |
| PL (1) | PL3592362T3 (enExample) |
| SG (1) | SG11201908181XA (enExample) |
| WO (1) | WO2018165048A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2893943C (en) | 2012-12-07 | 2021-03-02 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| JP6346904B2 (ja) | 2013-01-10 | 2018-06-20 | ベナトルクス ファーマシューティカルズ，インク． | ベータ−ラクタマーゼ阻害剤 |
| WO2014151958A1 (en) | 2013-03-14 | 2014-09-25 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| EP3882252B1 (en) | 2014-06-11 | 2025-11-19 | Venatorx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US9511142B2 (en) | 2014-06-11 | 2016-12-06 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| WO2017044828A1 (en) | 2015-09-11 | 2017-03-16 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| WO2017100537A1 (en) | 2015-12-10 | 2017-06-15 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| EP3494121B1 (en) | 2016-08-04 | 2021-10-06 | Venatorx Pharmaceuticals, Inc. | Boron-containing compounds |
| PH12019502037B1 (en) | 2017-03-06 | 2024-06-05 | Everest Medicines Singapore Pte Ltd | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
| EP3630783A4 (en) | 2017-05-26 | 2021-03-03 | Venatorx Pharmaceuticals, Inc. | PENICILLIN-BINDING PROTEIN INHIBITORS |
| US11332485B2 (en) | 2017-05-26 | 2022-05-17 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| WO2019226931A1 (en) | 2018-05-25 | 2019-11-28 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| US20220054513A1 (en) * | 2018-09-12 | 2022-02-24 | VenatoRx Pharmaceuticals, Inc. | Combination compositions comprising a beta-lactamase inhibitor |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1021454A (en) | 1911-01-23 | 1912-03-26 | Thomas Ernest Davis | Serving-table. |
| US7271186B1 (en) | 2002-12-09 | 2007-09-18 | Northwestern University | Nanomolar β-lactamase inhibitors |
| IN2012DN03023A (enExample) | 2004-01-26 | 2015-07-31 | Merck Sharp & Dohme | |
| NZ550522A (en) | 2004-03-30 | 2010-08-27 | Millennium Pharm Inc | Synthesis of boronic ester and acid compounds |
| CN1965838A (zh) * | 2005-11-17 | 2007-05-23 | 李海超 | 含头孢匹胺和β－内酰胺酶抑制剂的药物组合物 |
| CN101129382B (zh) | 2006-08-25 | 2013-12-25 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和缓冲组分的抗生素复方 |
| BRPI0820532A2 (pt) | 2007-11-13 | 2012-07-10 | Protez Pharmaceuticals Inc | inibidores de beta-lactamase |
| US20100120715A1 (en) | 2007-11-13 | 2010-05-13 | Burns Christopher J | Beta-lactamase inhibitors |
| JP5038509B2 (ja) | 2008-01-18 | 2012-10-03 | メルク・シャープ・エンド・ドーム・コーポレイション | β−ラクタマーゼ阻害剤 |
| US20100292185A1 (en) | 2009-05-12 | 2010-11-18 | Burns Christopher J | Beta-lactamase inhibitors |
| RU2599791C2 (ru) | 2010-08-10 | 2016-10-20 | Ремпекс Фармасьютикэлз, Инч. | Циклические бороновые кислотно-эфирные производные и их использование в терапии |
| AU2011373912B2 (en) * | 2011-07-26 | 2016-09-29 | Wockhardt Limited | Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor |
| WO2013053372A1 (en) | 2011-10-13 | 2013-04-18 | Therabor Pharmaceuticals | Boronic acid inhibitors of beta-lactamases |
| KR101288157B1 (ko) | 2011-12-07 | 2013-07-19 | 백병하 | 기존 세파계 항생제 및 베타 락타마제 저해제로 배합된 내성균주에 기인한 감염증의 치료 및 예방을 위한 복합항생제 |
| JP5798495B2 (ja) | 2012-01-13 | 2015-10-21 | 住友理工株式会社 | 配線体接続構造体 |
| EP2814483A2 (en) | 2012-02-15 | 2014-12-24 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
| DE102012101680A1 (de) | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat |
| CA2893943C (en) | 2012-12-07 | 2021-03-02 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| JP6324409B2 (ja) | 2013-01-04 | 2018-05-16 | レンペックス・ファーマシューティカルズ・インコーポレイテッド | ボロン酸誘導体及びその治療的使用 |
| AU2014204045B2 (en) | 2013-01-04 | 2018-10-18 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| JP6346904B2 (ja) | 2013-01-10 | 2018-06-20 | ベナトルクス ファーマシューティカルズ，インク． | ベータ−ラクタマーゼ阻害剤 |
| WO2014151958A1 (en) | 2013-03-14 | 2014-09-25 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| WO2015051101A1 (en) * | 2013-10-02 | 2015-04-09 | Cubist Pharmaceuticals, Inc. | B-lactamase inhibitor picoline salt |
| WO2015157618A1 (en) | 2014-04-11 | 2015-10-15 | The Texas A&M University System | Novel inhibitors of the new delhi metallo beta lactamase (ndm-1) |
| EP3882252B1 (en) | 2014-06-11 | 2025-11-19 | Venatorx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US20150361107A1 (en) | 2014-06-11 | 2015-12-17 | VenatoRx Pharmaceuticals, Inc. | Orally bioavailable beta-lactamase inhibitors |
| EP3189841B1 (en) | 2014-09-04 | 2023-11-22 | Shionogi & Co., Ltd. | Pharmaceutical preparation comprising cephalosporin having catechol groups |
| US10364257B2 (en) | 2014-12-19 | 2019-07-30 | Rempex Pharmaceuticals, Inc. | Apparatus and continuous flow process for production of boronic acid derivatives |
| WO2017044828A1 (en) | 2015-09-11 | 2017-03-16 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| CN105801610B (zh) | 2016-04-19 | 2018-05-18 | 武汉维舜医药科技有限公司 | 新型广谱β-内酰胺酶抑制剂 |
| JP7060245B2 (ja) | 2016-06-30 | 2022-04-26 | キューペックス バイオファーマ， インコーポレイテッド | ボロン酸誘導体およびその治療的使用 |
| EP3494121B1 (en) | 2016-08-04 | 2021-10-06 | Venatorx Pharmaceuticals, Inc. | Boron-containing compounds |
| PH12019502037B1 (en) | 2017-03-06 | 2024-06-05 | Everest Medicines Singapore Pte Ltd | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
| WO2019226931A1 (en) | 2018-05-25 | 2019-11-28 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| US20220054513A1 (en) | 2018-09-12 | 2022-02-24 | VenatoRx Pharmaceuticals, Inc. | Combination compositions comprising a beta-lactamase inhibitor |
| AU2019386849B2 (en) | 2018-11-29 | 2025-07-24 | VenatoRx Pharmaceuticals, Inc. | Combination compositions comprising a beta-lactamase inhibitor and uses thereof |
-
2018
- 2018-03-05 PH PH1/2019/502037A patent/PH12019502037B1/en unknown
- 2018-03-05 MY MYPI2019005139A patent/MY196966A/en unknown
- 2018-03-05 WO PCT/US2018/020968 patent/WO2018165048A1/en not_active Ceased
- 2018-03-05 JP JP2019547093A patent/JP7634934B2/ja active Active
- 2018-03-05 HR HRP20250459TT patent/HRP20250459T1/hr unknown
- 2018-03-05 EP EP18763383.9A patent/EP3592362B1/en active Active
- 2018-03-05 CN CN202311312855.3A patent/CN117398398A/zh active Pending
- 2018-03-05 SG SG11201908181X patent/SG11201908181XA/en unknown
- 2018-03-05 PL PL18763383.9T patent/PL3592362T3/pl unknown
- 2018-03-05 CA CA3055253A patent/CA3055253A1/en active Pending
- 2018-03-05 BR BR112019018447-3A patent/BR112019018447A2/pt active IP Right Grant
- 2018-03-05 IL IL268981A patent/IL268981B2/en unknown
- 2018-03-05 US US16/491,116 patent/US11091505B2/en active Active
- 2018-03-05 ES ES18763383T patent/ES3015371T3/es active Active
- 2018-03-05 MA MA047743A patent/MA47743A/fr unknown
- 2018-03-05 CN CN201880030083.5A patent/CN110678186A/zh active Pending
- 2018-03-05 KR KR1020197029086A patent/KR102603489B1/ko active Active
- 2018-03-05 AU AU2018230991A patent/AU2018230991B2/en active Active
-
2021
- 2021-06-21 US US17/353,377 patent/US11820784B2/en active Active
-
2023
- 2023-01-20 JP JP2023007546A patent/JP2023061946A/ja active Pending
- 2023-03-22 IL IL301591A patent/IL301591B1/en unknown
- 2023-09-27 US US18/476,050 patent/US12187752B2/en active Active
-
2024
- 2024-11-25 US US18/959,220 patent/US20250320235A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019018447A2 (pt) | formas sólidas e composições de combinação compreendendo um inibidor da beta-lactamase e usos das mesmas | |
| US10189833B2 (en) | Solid forms of a compound modulating kinases | |
| JP2013063999A (ja) | 抗核形成剤を含有する医薬組成物 | |
| JP2025020280A (ja) | ニコチニルアルコールエーテル誘導体のマレイン酸塩、その結晶形、及びその使用 | |
| BR112012013325B1 (pt) | Composição farmacêutica e uso | |
| WO2021074357A1 (en) | Thiophene derivatives for use in treating portal inflammation and fibrosis | |
| CN114349745B (zh) | 一种用于治疗心肌缺血的药物及其制备方法 | |
| CN115536654A (zh) | 小檗碱橙皮素盐晶型及其制备方法和其组合物与应用 | |
| EA048377B1 (ru) | Твердые формы и комбинированные композиции, содержащие ингибитор бета-лактамазы, и их применения | |
| HK40013654A (en) | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof | |
| EA042812B1 (ru) | Твердые формы и комбинированные композиции, содержащие ингибитор бета-лактамазы, и их применения | |
| HK40020554A (en) | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof | |
| HK40020554B (en) | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof | |
| TW202500163A (zh) | 固體形式 | |
| WO2017000270A1 (zh) | 枸橼酸舍曲林的2种晶型及其制备方法 | |
| BR112017008903B1 (pt) | Formas cristalinas de maltol férrico | |
| BR112019015487A2 (pt) | Formas cristalinas de tebipenem pivoxil, composições incluindo as mesmas, métodos de fabricação e métodos de uso | |
| BR122023014589B1 (pt) | Usos de formulação farmacêutica que compreende di-hidrato de monocloridrato de 2-((1-(2-(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil) isoindolin-1-ona | |
| NZ759132A (en) | Solid forms of { [5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid, compositions, and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/03/2018, OBSERVADAS AS CONDICOES LEGAIS |